In glioblastoma, the N6-methyladenosine (m6A)-modified LINREP interacts with the PTBP1/HuR complex and protects PTBP1 from ubiquitin-mediated degradation, thereby promoting tumor progression and potentially serving as a novel therapeutic target [62]. This evidence concerns the gene PTBP1 and neoplasm.